首页 | 本学科首页   官方微博 | 高级检索  
     

Comparison of diagnosis value for new onset myasthenia gravis by many clinical auxiliary examinations
引用本文:Jian Yin,Shiguang Wen,Yinhong Liu,Cuidi Wang,Hua Zhang,Hong Guo,Xianhao Xu. Comparison of diagnosis value for new onset myasthenia gravis by many clinical auxiliary examinations[J]. 中国神经再生研究, 2007, 2(7): 446-448. DOI: 10.1016/S1673-5374(07)60087-5
作者姓名:Jian Yin  Shiguang Wen  Yinhong Liu  Cuidi Wang  Hua Zhang  Hong Guo  Xianhao Xu
作者单位:Department of Neurology, Beijing Hospital, Ministry of Health, Beijing 100730, China
摘    要:
BACKGROUND: The clinical values of neostigmine test, clinical electrophysiologic study and acetylcholine receptor antibody detection in diagnosing myasthenia gravis (MG) found newly are unclear in China. OBJECTIVE: To investigate the reference value of common clinical diagnosis parameters in correctly diagnosing untreated MG found newly. DESIGN: Retrospective case analysis.SETTING: Department of Neurology, Beijing Hospital, Ministry of Health. PARTICIPANTS: Totally 156 outpatients with MG admitted to Department of Neurology, Beijing Hospital, Ministry of Health between January 1999 and December 2002. The involved patients, 72 males and 84 females, were aged 2–79 years. They were classified according to Osserman's criteria: ⅡA 72,ⅡB 76, Ⅲ 3 and Ⅳ 5. They were all subjected to being inquired of disease history, neostigmine test, and acetylcholine receptor antibody detection, met the diagnosis criteria of Neuroimmunology Committee of China, and confirmed by clinical electrophysiologic detections; Informed consents were obtained from all the involved subjects. METHODS: ①After admission, every patient was intramuscularly injected with 1.5 mg neostigmine; If the patient was a child, the injection dose was decreased according to his/her age. If his/her score of any observation index after injection was improved ≥ 50% as compared with before injection , his positive index was set as positive. Positive neostigmine test was set if there was one positive index. ②Repetitive nerve stimulation and single fiber electromyography were performed with Dantec Keypoint electromyogram (EMG) apparatus. ③Acetylcholine receptor antibody was detected by ELISA method. MAIN OUTCOME MEASURES: Clinical absolute and relative scores of MG, acetylcholine receptor antibody level, and repetitive nerve stimulation and single fiber electromyography examination results.RESULTS: The positive rates of neostigmine test, repetitive nerve stimulation and single fiber electromyography examination for MG were 86.5%, 82.6%, and 69.2%, respectively, and the positive rate of acetylcholine receptor antibody was 78.8%. CONCLUSION: Standardized neostigmine test has the highest sensitivity to diagnose MG.

关 键 词:肌无力症 肌电扫描术 乙酰胆碱 诊断价值
收稿时间:2007-04-11
修稿时间:2007-04-112007-05-10

Comparison of diagnosis value for new onset myasthenia gravis by many clinical auxiliary examinations
Jian Yin,Shiguang Wen,Yinhong Liu,Cuidi Wang,Hua Zhang,Hong Guo and Xianhao Xu. Comparison of diagnosis value for new onset myasthenia gravis by many clinical auxiliary examinations[J]. Neural Regeneration Research, 2007, 2(7): 446-448. DOI: 10.1016/S1673-5374(07)60087-5
Authors:Jian Yin  Shiguang Wen  Yinhong Liu  Cuidi Wang  Hua Zhang  Hong Guo  Xianhao Xu
Affiliation:Department of Neurology, Beijing Hospital, Ministry of Health;Department of Neurology, Beijing Hospital, Ministry of Health;Department of Neurology, Beijing Hospital, Ministry of Health;Department of Neurology, Beijing Hospital, Ministry of Health;Department of Neurology, Beijing Hospital, Ministry of Health;Department of Neurology, Beijing Hospital, Ministry of Health;Department of Neurology, Beijing Hospital, Ministry of Health
Abstract:
BACKGROUND: The clinical values of neostigmine test, clinical electrophysiologic study and acetylcholine receptor antibody detection in diagnosing myasthenia gravis (MG) found newly are unclear in China.OBJECTIVE: To investigate the reference value of common clinical diagnosis parameters in correctly diagnosing untreated MG found newly.DESIGN: Retrospective case analysis.SETTING: Department of Neurology, Beijing Hospital, Ministry of Health.PARTICIPANTS: Totally 156 outpatients with MG admitted to Department of Neurology, Beijing Hospital,Ministry of Health between January 1999 and December 2002. The involved patients, 72 males and 84 females, were aged 2 - 79 years. They were classified according to Osserman's criteria: ⅡA 72, ⅡB 76, Ⅲ3 and Ⅳ 5. They were all subjected to being inquired of disease history, neostigmine test, and acetylcholine receptor antibody detection, met the diagnosis criteria of Neuroimmunology Committee of China, and confirmed by clinical electrophysiologic detections; Informed consents were obtained from all the involved subjects.METHODS: ①After admission, every patient was intramuscularly injected with 1.5 mg neostigmine; If the patient was a child, the injection dose was decreased according to his/her age. If his/her score of any observation index after injection was improved ≥ 50% as compared with before injection , his positive index was Set as positive. Positive neostigmine test was set if there was one positive index. ②Repetitive nerve stimulation and single fiber electromyography were performed with Dantec Keypoint electromyogram (EMG) apparatus. ③Acetylcholine receptor antibody was detected by ELISA method.MAIN OUTCOME MEASURES: Clinical absolute and relative scores of MG, acetylcholine receptor antibody level, and repetitive nerve stimulation and single fiber electromyography examination results.RESULTS: The positive rates of neostigmine test, repetitive nerve stimulation and single fiber electromyography examination for MG were 86.5%, 82.6%, and 69.2%, respectively, and the positive rate of acetylcholine receptor antibody was 78.8%.CONCLUSION: Standardized neostigmine test has the highest sensitivity to diagnose MG.
Keywords:myasthenia gravis  electromyography  acetylcholine receptor antibody
本文献已被 维普 万方数据 ScienceDirect 等数据库收录!
点击此处可从《中国神经再生研究》浏览原始摘要信息
点击此处可从《中国神经再生研究》下载全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号